Guardant Health, Inc. announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from circulating tumor DNA (ctDNA).
The updated NCCN CRC Screening Guidelines recommend the Shield test for screening every three years. This inclusion is a major clinical validation for the blood-based test, which offers a more convenient and pleasant screening option for millions of eligible Americans.
AmirAli Talasaz, Guardant Health co-CEO, stated that this guideline inclusion is a pivotal step for more patients to benefit from the test. The NCCN cited Guardant’s landmark ECLIPSE study, published in the New England Journal of Medicine, which demonstrated Shield's high effectiveness in detecting CRC with 83% sensitivity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.